StockNews.com Begins Coverage on Diffusion Pharmaceuticals (NASDAQ:DFFN)
StockNews.com Begins Coverage on Diffusion Pharmaceuticals (NASDAQ:DFFN)
Equities researchers at StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
Separately, HC Wainwright upgraded shares of Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price objective for the company in a research report on Tuesday, August 16th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Stock Up 3.3 %
Shares of Diffusion Pharmaceuticals stock opened at $6.30 on Thursday. Diffusion Pharmaceuticals has a fifty-two week low of $5.10 and a fifty-two week high of $28.25. The business has a 50-day moving average price of $7.01 and a 200 day moving average price of $11.48. The firm has a market cap of $12.85 million, a P/E ratio of -0.51 and a beta of 1.53.
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($2.06) EPS for the quarter, missing analysts' consensus estimates of ($1.77) by ($0.29). As a group, equities research analysts anticipate that Diffusion Pharmaceuticals will post -8.43 earnings per share for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP acquired a new position in shares of Diffusion Pharmaceuticals in the 2nd quarter valued at about $71,000. JPMorgan Chase & Co. purchased a new stake in shares of Diffusion Pharmaceuticals during the first quarter worth $106,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after purchasing an additional 101,100 shares during the last quarter. Hedge funds and other institutional investors own 10.25% of the company's stock.
Diffusion Pharmaceuticals Company Profile
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Stories
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com的股票研究人員發起了對擴散製藥(納斯達克:DFFN-GET評級)在週四發佈給投資者的一份研究報告中。該經紀公司對該股設定了“持有”評級。
另外,在8月16日(週二)的一份研究報告中,HC Wainwright將Diffsion PharmPharmticals的股票評級從中性上調至買入,並為該公司設定了9.50美元的目標價。
到達擴散製藥公司警報:擴散製藥類股上漲3.3%
週四,擴散製藥公司的股票開盤報6.30美元。Diffect PharmPharmticals的52周低點為5.10美元,52周高位為28.25美元。該業務的50日移動均線價格為7.01美元,200日移動均線價格為11.48美元。該公司市值為1285萬美元,本益比為-0.51,貝塔係數為1.53。
擴散製藥(納斯達克:DFFN-GET評級)最近一次發佈季度收益報告是在8月11日(星期四)。該公司公佈本季度每股收益為2.06美元,低於分析師普遍預期的每股收益1.77美元和0.29美元。作為一個整體,股票研究分析師預計,擴散製藥公司本年度的每股收益將達到8.43美元。機構資金流入和流出
機構投資者和對沖基金最近調整了對該公司的持股。Trexquant Investment LP在第二季度收購了擴散製藥公司股票的新頭寸,價值約7.1萬美元。摩根大通(JPMorgan Chase&Co.)在第一季度購入了價值10.6萬美元的新股。最後,復興科技有限責任公司在第一季度增持了8.3%的擴散製藥股份。復興科技有限責任公司在上個季度又購買了101,100股後,現在擁有1,324,202股該公司股票,價值331,000美元。對沖基金和其他機構投資者持有該公司10.25%的股票。
擴散製藥公司簡介
(獲取評級)
擴散製藥公司是一家生物製藥公司,該公司開發新的療法,以增強人體輸送氧氣的能力。它的主要候選產品是反式番茄酸鈉,開發這種藥物是為了促進氧氣向組織的擴散,以及治療新冠肺炎病。擴散製藥公司成立於2001年,總部設在弗吉尼亞州夏洛茨維爾。
專題報道
- 免費獲取StockNews.com關於擴散藥物的研究報告(DFFN)
- 這家醫療設備製造商準備好繼續反彈了嗎?
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬?
- 具有有趣內幕活動的四隻廉價股票
- 隨著收購傳言的甚囂塵上,Lyft能否成功?
獲得《擴散醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對擴散製藥及相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧